Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Potnak self harm how worse can it really get if good news is coming or bad we carnt change that but we can change the chairman if good news they will hopefully bring more than what has been brought so far and improve investor relations if bad they can then build agin instead of sitting on their hands doing sweet FA . As is showing this morning I believe a call for a EGM is not far away and if it came before new and Parker went it would be his own doing
GLA
Good point but again shows no forward thinking why stop at 3m when they know how much a trial costs again no work put in took the easy option ,apart from the abysmal SP everything good here hope your enjoying your retirement
GLA
Colbalt facts
Agile funding lie
Going into clinic 2022 lie
Peel hunt institutional investors lie
Consolidate to stop manipulation lie
Brought HNWI to SAR NO
Missed dead lines 90pc of time correct
1802 lies been ongoing for 3 years
But be free to back the chairman with facts
Ps seen you had been very happy on the Val board
GLA
Look at what he did to MGC and when they consolidated and the same happening here absolute shambles time to get a full time CEO in who is respected and has contacts he has been living off one deal .Out of touch and needs to go
GLA
Damion the BOD should of been forward thinking to get 1802 in tox studies but with no funding imho it has been shelved until we get the money required
Scandalous if you ask me a first in class especially with cancer in mind imagine the interested parties we could have attracted then you only need to see their faces when I asked the Q at the AGM. And the reply given
GLA
Not far from the 30s and if we’re not expecting news till as some say April will we be consolidating again to make us attractive to investors and to stop manipulation of the SP as we did last time ??
Asking for a friend
GLA
Stif you may be right but what you also need to remember is with just over 70m shares upon good news the mms are going to have to raise this a hell of a lot for many shareholders to relinquish their shares just look at the hnwi and at what price they would have to get just to break even along with many others
GLA
Https://www.abpi.org.uk/publications/guidelines-for-phase-i-clinical-trials-2018-edition/
An interesting in depth read
GLA
Totally agree scientists in the lab and do we need someone more forward thinking at the helm is it time to start sharpening the pitchfork ?
Remember they work for us the share holders will wait to see what h he append to sp after 1801 news if no good maybe time to call an EGM
GLA
Https://endpts.com/bristol-myers-opdivo-fails-part-two-of-post-kidney-cancer-surgery-test-as-competitor-merck-touts-new-survival-data/
Maybe BMS s failure could be a significant opportunity for Sar s 1802 to be resurrected and fully developed in collaboration in the joint targeting of Kidney cancer one of Sar s previously stated targets for SDC 1802 .An option to be considered and get this molecule up and running
GLA
Since the start of the trial we have only dropped 60pc and if some saying no news till March looks like we are only heading one way, looks like puma could be right and we hit the 30s by then . But will we get the big rise s we are hoping to see or just raped by the mms seems amazing how this share is getting mullered on little trading
GLA
See the board buzzing again one day like days of old or like the HE1 board today even though not in is great to see some making money on aim be interesting to see what happens over there the next few days and what impact on Sar once we have the next RNS ref 1801 even 737 could see us move on a decent up front payment once things get moving
GLA
Question 10:
Assuming the Board has a strategy in place for the commercialisation of SDC-1801, could you outline some of the factors taken into consideration during the planning?
Our Board has conducted market research to identify which companies are most likely to consider in-licensing a product such as SDC-1801 and to understand the strengths and weaknesses of our competitors. We also have a continued dialogue with potential partners to understand what they need to see in a data package before committing to a licensing deal.
GLA